Results 281 to 290 of about 127,002 (321)

RNA G‑Quadruplex Reprogramming with Guanine-Rich Antisense Oligonucleotides Inhibits Monoamine Oxidase B's Translation. [PDF]

ACS Bio Med Chem Au
Turcotte MA, Perreault JP.
europepmc   +1 more source

Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies. [PDF]

CNS Neurosci Ther
Quilón PG, Volpedo G, Cappato S, Ferrera L, Zara F, Bocciardi R, Riva A, Striano P.   +7 more
europepmc   +1 more source

Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference. [PDF]

Front Endocrinol (Lausanne)
Golounina O, Minniakhmetov I, Salakhov R, Khusainova R, Zakharova E, Bychkov I, Mokrysheva N.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antisense Oligonucleotides

Nephron Experimental Nephrology, 1998
Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA which encodes the target gene. There are a few possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of action for antisense ...
N, Kashihara, Y, Maeshima, H, Makino
openaire   +2 more sources

Antisense-Oligonucleotide Therapy

New England Journal of Medicine, 1996
Many pharmacologic advances involve creating compounds that bind and disable proteins. Such compounds include propranolol, which blocks the β-adrenergic receptor; cimetidine, which blocks the H2 receptor; calcium-channel blockers; angiotensin-converting–enzyme inhibitors; and inhibitors of the H+/K+–ATPase pump.
F K, Askari, W M, McDonnell
openaire   +2 more sources

Antisense Oligonucleotide Drug Design

Current Pharmaceutical Design, 2004
Maneuvering single gene expression is not only an optimal way to study gene function but also an ambitious goal, which will lead to the treatment of a variety of human diseases whose main pathogenetic event is a genetic alteration. The recent efforts focusing on the genome project have led to array based, high throughput, gene expression analysis ...
SCHIAVONE, NICOLA, DONNINI, MARTINO, A. Nicolin, CAPACCIOLI, SERGIO   +3 more
openaire   +4 more sources

Antisense oligonucleotides.

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 1997
Among the approaches which have been followed to convert a natural antisense phosphodiester oligonucleotide into a potential therapeutic agent, conjugation chemistry seems to be one of the most attractive. Indeed, natural phosphodiester oligonucleotide have the ideal properties (sequence specific hybridization, RNaseH activation, low or no toxicity ...
openaire   +3 more sources

Pharmacokinetics of Antisense Oligonucleotides

Clinical Pharmacokinetics, 1995
Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases. Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes.
S, Agrawal, J, Temsamani, W, Galbraith, J, Tang   +3 more
openaire   +2 more sources

Antisense Anticancer Oligonucleotide Therapeutics

Current Cancer Drug Targets, 2001
Recent progress made in molecular biology, biotechnology, and genetics, especially in identifying, cloning, sequencing and characterization of normal and pathogenic genes, has led to the development of genetic therapy. Major efforts in the field can be summarized in two general approaches: gene therapy and antisense therapy. The second is to deliver to
H, Wang, G, Prasad, J K, Buolamwini, R, Zhang   +3 more
openaire   +2 more sources